The development of ALK sequencing has aided the precision treatment of ALK+ ALCL and has revealed novel drug resistance mutations; the elucidation of ALK TKI resistance mechanisms will facilitate the development of new treatment strategies. This evidence concerns the gene ALK and anaplastic large cell lymphoma.